MM 201
Alternative Names: MM-201Latest Information Update: 30 Aug 2019
Price :
$50 *
At a glance
- Originator Merrimack Pharmaceuticals
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer